Daniel Yeager Appointed New Senior V.P. of Market Development Of The Wound Pros

December 23, 2020

Daniel Yeager is the new Senior Vice President of Market Development of The Wound Pros, who specializes in the treatment and management of chronic non-healing wounds in long-term care facilities. The physician-owned and managed company is also an accredited supplier of Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) and a participating Medicare Part B provider.

Daniel Yeager is a business professional with a vast amount of experience in sales, marketing, training, business development, and strategic planning. He graduated with honors from Capella University, Minnesota, earning a Bachelor’s Degree in Business Administration. With almost ten years of work experience, Daniel has developed a unique skill set that portrays excellence in his work ethic, dedication, and commitment to professional and personal growth. As Senior Vice President of Market Development, he will prioritize the continuous growth and refinement of The Wound Pros market expansion and business strategies.

Despite the COVID-19 pandemic, 2020 has been a remarkable year for The Wound Pros. The company has rapidly grown and expanded its operations into 16 states of the U.S. This year, it introduced RITA, an AI-enabled wound measurement app for assessing patients’ wounds at the bedside or remotely and generating relevant documentation to support wound care teams. In response to the pandemic, it developed a camera-based health and wellness monitoring app for tracking variations in users’ vital signs, including heart rate, respiratory rate, heart rate variability (HRV), oxygen saturation, mental stress, and blood pressure. Routine monitoring of vital signs, particularly oxygen saturation can effectively predict COVID-19 infection to curb the spread.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version